Study sheds light on lung adenocarcinoma-to-squamous transdifferentiation mechanism
AKT and EZH2 are identified as potential therapeutic targets to limit acquired resistance to osimertinib in patients with EGFR-mutated tumours of the lung
Novel concepts on the horizon for the diagnosis and treatment of mesothelioma
Malignant pleural mesothelioma is a rare and fatal disease with very little improvement in survival in recent years, mirroring very limited therapeutic advances. After a long-awaited time, improvement in patient survival was achieved with the introduction of nivolumab plus ipilimumab in the first-line setting, as demonstrated in the CheckMate 743 trial.
Adjuvant atezolizumab lowers relapse rate in resected NSCLC
An exploratory analysis from the IMpower010 trial adds support to the use of post-chemotherapy adjuvant immunotherapy for selected early stage non-small-cell lung cancer
Positive results with immunotherapy rechallenge in NSCLC
Results from the ATALANTE-1 and MRTX-500 trials show efficacy improvements with immunotherapy in patients post-immune checkpoint inhibitor failure
Positive early clinical results for amivantamab plus lazertinib in NSCLC
Two phase I trials in patients with advanced EGFR-mutated NSCLC demonstrate promising potential of targeted therapy with amivantamab plus lazertinib
CheckMate 743 reinforces the role of immunotherapy in first-line mesothelioma
Nearly 1 in 4 patients with pleural malignancy continue to benefit from nivolumab plus ipilimumab at 3 years
Lung cancer screening – an accessible option to all at-risk smokers?
While mature data from trials have demonstrated that periodic rounds of low-dose CT scan reduce lung-cancer related mortality, major issues are now implementation of screening on a large-scale and how to engage the target population
Could the daunting biology of small-cell lung cancer provide the key to elucidating drug resistance?
At ELCC 2021, Prof. Fiona Blackhall sees hope for improving patients’ poor prognoses on the horizon
The “holy grail” of lung cancer research: bring the immune system into every tumour
With multiple new therapies available, Prof. Johan Vansteenkiste says the search is on for biomarkers to better match patients to treatments
What should oncologists know about e-cigarettes?
Electronic nicotine delivery systems (ENDS) are battery-powered products that create an aerosol by heating a liquid consisting of propylene glycol and vegetable glycerin and flavouring agents. The liquid may or may not (but usually does) contain nicotine, at variable doses. Differently from conventional cigarettes, there is no combustion of tobacco in ENDS, thus making people think they cause less harm. However, the varying voltage that is applied to the liquid creates a mixture of potentially toxic substances in the aerosols that are then inhaled by users.